

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: October 18, 2010

Signature: /Therese M. Finan/  
(Therese M. Finan)

Docket No.: 026038.0248PTUS  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Hilde Azijn et al.

Application No.: 10/519,436

Confirmation No.: 7541

Filed: December 22, 2004

Art Unit: 1648

For: NEW MUTATIONAL PROFILES IN HIV-1  
REVERSE TRANSCRIPTASE  
CORRELATED WITH PHENOTYPIC  
DRUG RESISTANCE

Examiner: L. W. Z. Humphrey

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Commissioner:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be considered for this application.

This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action after the filing of a Request for Continued Examination under 37 CFR 1.114 (37 CFR 1.97(b)(4)).

In accordance with 37 CFR § 1.98(a)(2)(ii), Applicants have not submitted copies of U.S. patents and U.S. published patent applications. Similarly, copies of Office Actions issued in commonly-owned U.S. patent applications directed to similar subject matter, also stored and available to the Examiner in electronic form in the Office's IFW system, have not been submitted (69 FR 56481, 56510, Sept. 21, 2004). Applicants submit herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

Books referenced in the specification for general, conventional scientific techniques, specifically, ALBERTS, The Molecular Biology of the Cell, Garland Publishing, New York, 1996, are not relevant to the patentability of the claimed subject matter of the above-referenced application and have not been listed or submitted. If the Examiner requires a copy of this book, one will be furnished upon request.

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication, or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98, and the Examiner is respectfully requested to consider the listed references.

Applicants believe no fee is due with this submission. If a fee is due, however, the U.S. Patent and Trademark Office is authorized to charge any additional fees that may be required in conjunction with this submission to Deposit Account Number 50-2228, under Order No. 026038.0248PTUS.

Respectfully submitted,

Dated: October 18, 2010

By: /Therese M. Finan/

Therese M. Finan

Registration No.: 42,533

PATTON BOGGS LLP

8484 Westpark Drive, 9th Floor

McLean, Virginia 22102

(703) 744-8069

(703) 744-8001 (Fax)

Attorney for Applicants

**Customer No. 32042**